Virtual Coaching to Enhance Diabetes Care.

abstract：BACKGROUND:The aim of this investigation was to assess clinical predictors of the glycosylated hemoglobin (HbA1C) response after the addition of a thiazolidinedione (TZD) to a biguanide, a sulfonylurea, or both in subjects with type 2 diabetes. METHODS:Chart review (n = 68 physicians) was used to identify consecutive ...

journal_title：Diabetes technology & therapeutics

authors： Izumi R,Hurt J,Maki KC,Bell M,Zavras AI,McCamish M

更新日期：2007-12-01 00:00:00

abstract：BACKGROUND:Relatively little is known about parents' or children's attitudes toward recruitment for, and participation in, studies of new diabetes technologies immediately after diagnosis. This study investigated factors affecting recruitment of participants for studies in newly diagnosed youth with type 1 diabetes. M...

journal_title：Diabetes technology & therapeutics

authors： Farrington C,Allen J,Tauschmann M,Randell T,Trevelyan N,Hovorka R

更新日期：2016-09-01 00:00:00

abstract：:Chronic hyperglycemia, as assessed by hemoglobin A1c (HbA1c) levels, has been associated with the development of microvascular and macrovascular complications of diabetes. Several studies have shown that acute hyperglycemia can add to the effect of chronic hyperglycemia in inducing tissue damage. Acute hyperglycemia c...

journal_title：Diabetes technology & therapeutics

authors： Marcovecchio ML,Lucantoni M,Chiarelli F

更新日期：2011-03-01 00:00:00

abstract：:Skin integrity and diabetes device placement are ongoing concerns for people with diabetes who utilize continuous glucose monitors (CGMs) and continuous subcutaneous insulin infusion pumps. This is especially significant for individuals with skin sensitivities, pediatric patients, and those who use devices chronically...

journal_title：Diabetes technology & therapeutics

authors： Messer LH,Berget C,Beatson C,Polsky S,Forlenza GP

更新日期：2018-06-01 00:00:00

abstract：: Background: Glycemic variability (GV) is an important component of glycemic control for patients with type 1 diabetes (T1D). The inadequacy of existing measurements lies in the fact that they view the variability from different aspects, so that no consensus has been reache...

journal_title：Diabetes technology & therapeutics

authors： Zheng F,Jalbert M,Forbes F,Bonnet S,Wojtusciszyn A,Lablanche S,Benhamou PY

更新日期：2020-04-01 00:00:00

abstract：:Recent years have brought about an explosion in the number of companies offering connected diabetes care products, defined as digital diabetes management systems based around (1) smartphone apps, (2) devices with built-in connectivity, and (3) remote human and automated coaching and support. These nascent models aim t...

journal_title：Diabetes technology & therapeutics

authors： Levine BJ,Close KL,Gabbay RA

更新日期：2020-01-01 00:00:00

abstract：OBJECTIVES:Hyperglycemia is a prominent feature among patients exposed to major stress such as in cardiac surgery. The implementation of a continuous glucose monitoring system (CGMS) for glucose monitoring during cardiac surgery was assessed. SUBJECTS AND METHODS:Fifty-nine consecutive patients who underwent cardiac s...

journal_title：Diabetes technology & therapeutics

authors： Kalmovich B,Bar-Dayan Y,Boaz M,Wainstein J

更新日期：2012-03-01 00:00:00

abstract：:This paper presents a critical review of continuous glucose monitoring studies that address accuracy, utility in assessing glucose variability, detection of hypoglycemia for improved metabolic control or reduced glucose variability, impact on quality of life, reduced fear of hypoglycemia, and applicability in helping ...

journal_title：Diabetes technology & therapeutics

authors： Reach G

更新日期：2008-04-01 00:00:00

abstract：BACKGROUND:Glucose variability has been identified as a predictor of hypoglycemia and has been associated with mortality in critically ill patients without diabetes. A popular metric to quantify glucose variability is the mean amplitude of glycemic excursions (MAGE). The "ruler and pencil" approach to calculate MAGE is...

journal_title：Diabetes technology & therapeutics

authors： Sechterberger MK,Luijf YM,Devries JH

更新日期：2014-02-01 00:00:00

abstract：BACKGROUND:Patients undergoing intensive insulin therapy may have blood glucose (BG) samples drawn from arterial, capillary, or venous sources. This study compared capillary and venous BG across a range of glucose concentrations and under conditions of rapid change in BG. METHODS:Following a 10-h fast, 40 adult patien...

journal_title：Diabetes technology & therapeutics

authors： Kempe K,Price D,Ellison J,Marhoul J,Morrow L,Win K,Kuschma K,Hompesch M

更新日期：2009-10-01 00:00:00

abstract：BACKGROUND:There is an unmet need for a modular artificial pancreas (AP) system for clinical trials within the existing regulatory framework to further AP research projects from both academia and industry. We designed, developed, and tested the interoperable artificial pancreas system (iAPS) smartphone app that can int...

journal_title：Diabetes technology & therapeutics

authors： Deshpande S,Pinsker JE,Zavitsanou S,Shi D,Tompot R,Church MM,Andre C,Doyle FJ 3rd,Dassau E

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Drugs with unspecific stimulating effects on beta-cell secretion increase the homeostasis model assessment (HOMA)-B score, indicating improved beta-cell "function." We investigated whether the beta-cell protection provided by adding pioglitazone (PIO) to glimepiride (GLIM) in comparison to up-titrating the G...

journal_title：Diabetes technology & therapeutics

authors： Pfützner A,Derwahl M,Jacob S,Hohberg C,Blümner E,Lehmann U,Fuchs W,Forst T

更新日期：2010-08-01 00:00:00

abstract：BACKGROUND:The present study evaluated the efficacy of biphasic human insulin 30 (BHI 30) in type 2 diabetes patients who had failed in therapy with two or more oral antidiabetes drugs (OADs). METHODS:This open-label, nonrandomized, 4-month, multicenter, clinical observational study was conducted in Shanghai, China. A...

journal_title：Diabetes technology & therapeutics

authors： Gu Y,Hou X,Zhang L,Pan J,Cai Q,Bao Y,Jia W

更新日期：2012-03-01 00:00:00

abstract：:Self-monitoring of blood glucose (SMBG) is universally considered to be an integral part of type 1 diabetes management and crucial for optimizing the safety and efficacy of complex insulin regimens. This extends to type 2 diabetes patients on intensive insulin therapy, and there is also a growing body of evidence sugg...

journal_title：Diabetes technology & therapeutics

authors： Czupryniak L,Barkai L,Bolgarska S,Bronisz A,Broz J,Cypryk K,Honka M,Janez A,Krnic M,Lalic N,Martinka E,Rahelic D,Roman G,Tankova T,Várkonyi T,Wolnik B,Zherdova N

更新日期：2014-07-01 00:00:00

abstract：:AIDA is a diabetes-computing program freely available from www.2aida.org on the Web. The software is intended to serve as an educational support tool, and can be used by anyone who has an interest in diabetes, whether they be patients, relatives, health-care professionals, or students. In previous "Diabetes Informatio...

journal_title：Diabetes technology & therapeutics

authors： Lehmann ED

更新日期：2003-01-01 00:00:00

abstract：:Continuous glucose monitoring (CGM) is a new tool that has recently become available to people with diabetes. Properly designing and conducting trials in order to answer important questions regarding the clinical usefulness of CGM is very difficult and fraught with many confounding variables and unique challenges. Ini...

journal_title：Diabetes technology & therapeutics

authors： Edelman SV,Bailey TS

更新日期：2009-06-01 00:00:00

abstract：BACKGROUND:The masked continuous glucose monitoring system (Masked-CGMS) differs from standard CGMSs in three ways: (1) there is no feedback to the user so that no immediate regimen changes can be made; (2) it can only be worn for up to 5 days; and (3) there are no alarms to warn of hyperglycemia or hypoglycemia. Since...

journal_title：Diabetes technology & therapeutics

authors： Duran-Valdez E,Burge MR,Broderick P,Shey L,Valentine V,Schrader R,Schade DS

更新日期：2014-05-01 00:00:00

abstract：BACKGROUND:Glutamic acid decarboxylase-65 (GAD65) is a major autoantigen in autoimmune diabetes and is discharged from injured islet beta cells. GAD65 may also be released by transplanted islets undergoing immunological rejection. To test hypotheses regarding the utility of GAD65 as a biomarker for transplant rejection...

journal_title：Diabetes technology & therapeutics

authors： Waldrop MA,Suckow AT,Hall TR,Hampe CS,Marcovina SM,Chessler SD

更新日期：2006-04-01 00:00:00

abstract：: Background: This observational study investigated whether the connected NovoPen® 6 could influence insulin regimen management and glycemic control in people with type 1 diabetes (T1D) using a basal-bolus insulin regimen and continuous glucose monitoring in a real-world set...

journal_title：Diabetes technology & therapeutics

authors： Adolfsson P,Hartvig NV,Kaas A,Møller JB,Hellman J

更新日期：2020-10-01 00:00:00

abstract：BACKGROUND:This study evaluated whether education and use of the advanced meter features of the CONTOUR(®) (Bayer HealthCare LLC, Diabetes Care, Tarrytown, NY) blood glucose monitoring system (BGMS) affect the frequency and pattern of blood glucose testing in insulin-using subjects with diabetes who routinely perform s...

journal_title：Diabetes technology & therapeutics

authors： Bergenstal RM,Bode BW,Tamler R,Trence DL,Stenger P,Schachner HC,Fullam J,Pardo S,Kohut T,Fisher WA

更新日期：2012-10-01 00:00:00

abstract：BACKGROUND:A1chieve(®) (Novo Nordisk A/S, Bagsværd, Denmark) was a prospective, multicenter, noninterventional study in 66,726 people with type 2 diabetes mellitus (T2DM) in 28 countries beginning biphasic insulin aspart 30 (aspart premix), insulin detemir, or insulin aspart in routine clinical care. SUBJECTS AND METH...

journal_title：Diabetes technology & therapeutics

authors： Shah S,Yang W,Hasan MI,Malek R,Molskov Bech O,Home P

更新日期：2013-11-01 00:00:00

abstract：OBJECTIVE:This study assessed the association of serum adiponectin with carotid intimal medial thickness (IMT) in Asian Indians with different grades of glucose intolerance. METHODS:Subjects with normal glucose tolerance (NGT) (n = 520), impaired glucose tolerance (IGT) (n = 115), and type 2 diabetes mellitus (T2DM) (...

journal_title：Diabetes technology & therapeutics

authors： Gokulakrishnan K,Indulekha K,Ganesan S,Anuradha S,Mohan V

更新日期：2010-02-01 00:00:00

abstract：BACKGROUND:Continuous subcutaneous insulin infusion (CSII) is an effective method of insulin substitution with increased risk of hypoglycemia and diabetic ketoacidosis (DKA) in rare situations. The lack of subcutaneous long-acting insulin and short half-life of serum insulin increases the risk of ketosis and DKA follow...

journal_title：Diabetes technology & therapeutics

authors： Alemzadeh R,Parton EA,Holzum MK

更新日期：2009-08-01 00:00:00

abstract：AIMS:This study assessed patient-reported outcomes in a multicenter study of adults with type 2 diabetes taking mealtime Technosphere(®) inhaled insulin (MannKind Corp., Valencia, CA) and basal insulin (insulin glargine) or premixed aspart insulin 70/30. METHODS:Subjects were 618 non-smoking adults with starting hemog...

journal_title：Diabetes technology & therapeutics

authors： Peyrot M,Rubin RR

更新日期：2011-12-01 00:00:00

abstract：OBJECTIVE:This study assessed the accuracy and reliability of three continuous glucose monitoring (CGM) systems. RESEARCH DESIGN AND METHODS:We studied the Animas® (West Chester, PA) Vibe™ with Dexcom® (San Diego, CA) G4™ version A sensor (G4A), the Abbott Diabetes Care (Alameda, CA) Freestyle® Navigator I (NAV), and ...

journal_title：Diabetes technology & therapeutics

authors： Luijf YM,Mader JK,Doll W,Pieber T,Farret A,Place J,Renard E,Bruttomesso D,Filippi A,Avogaro A,Arnolds S,Benesch C,Heinemann L,DeVries JH,AP@home consortium.

更新日期：2013-08-01 00:00:00

abstract：AIMS:Skin autofluorescence (AF) has been associated with complications of diabetes. We evaluated the influence of skin color and ethnicity on the association between skin AF and the presence of diabetes-related complications. MATERIALS AND METHODS:In a multiethnic type 2 diabetes cohort we investigated all patients wi...

journal_title：Diabetes technology & therapeutics

authors： Ahdi M,Gerdes VE,Graaff R,Kuipers S,Smit AJ,Meesters EW

更新日期：2015-02-01 00:00:00

abstract：:The peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor isoforms, including PPARgamma, PPARalpha, and PPARdelta, encoded by different genes. PPARs are ligand-regulated transcription factors that control gene expression by binding to specific response elements (PPREs) within promoters. P...

journal_title：Diabetes technology & therapeutics

authors： Berger J,Wagner JA

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:Gestational diabetes mellitus (GDM) is associated with adverse perinatal outcomes, if not treated. International guidelines recommend screening "all or high-risk women" at the initial prenatal visit, when a fasting plasma glucose (FPG) between 92 and 126 mg/dL is diagnostic for GDM. However, glucose testing ...

journal_title：Diabetes technology & therapeutics

authors： Festa R,Carta M,Ceriello A,Testa R

更新日期：2012-05-01 00:00:00

abstract：:With the expiration of patent protection for several originator insulin analog molecules, the availability of insulin analog copies is set to increase. Many regulatory authorities have developed, and continue to refine, guidelines for the approval of biosimilar insulin analogs. Aspects such as the structure, pharmacok...

journal_title：Diabetes technology & therapeutics

authors： Heinemann L,Fritz I,Khatami H,Edelman SV

更新日期：2017-02-01 00:00:00

abstract：:Innovo (Novo Nordisk A/S, Hillerød, Denmark) is a new insulin injection system that offers built-in memory and a large, clear display to provide patients with more control during insulin injections. The aim of this trial was to compare the efficacy and safety of Innovo and NovoPen 3 (Novo Nordisk A/S) in patients expe...

journal_title：Diabetes technology & therapeutics

authors： Valk NK,Cerny G,Sieber J,Lytzen L,Berg B

更新日期：2004-02-01 00:00:00